Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 2.6% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.7%.
The iShares Biotechnology ETF (IBB) slumped 5.7%.
In sector news, the US Food and Drug Administration said Tuesday it plans to expand its use of surprise inspections at foreign facilities that make food, essential medicines, and other medical products for US consumers.
In corporate news, NuCana (NCNA) shares tumbled 66% after it priced a $7 million registered direct offering.
Heron Therapeutics (HRTX) shares jumped past 13% after the firm said it reached a settlement agreement with Viatris' (VTRS) Mylan Pharmaceuticals to resolve patent litigation over the Cinvanti and Aponvie injectable emulsions. Viatris lost 0.8%.
Beam Therapeutics (BEAM) shares tumbled nearly 20% after it reported a wider Q1 loss compared with a year earlier.
Philips (PHG) shares fell 5.9% after it reported flat Q1 adjusted earnings per share, while sales declined.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。